Across TCGA pan-cancer cohorts, PLAC8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PLAC8 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PLAC8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLAC8 expression acts as an unfavorable survival marker.
LUSC, UCEC, and SCLC are the cancer types where PLAC8 Mutation most reproducibly stratifies survival.